NEW YORK, June 7, 2022– Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced that it has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors. New investors, including a large,